Imprimis NJOF, LLC recalled 596 boxes of intraocular injections on December 18, 2025. The recall affects products due to the presence of glass-like particles. Consumers should stop using the product immediately and contact their healthcare provider.
Presence of particulate matter - Glass like particles.
Consumers and healthcare providers should stop using this product immediately. Contact Imprimis NJOF, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Dexamethasone Moxifloxacin Ketorolac, 1 mg/mL, 0.5 mg/mL, 0.4 mg/mL, with model numbers Lot: 25APR001A and 25APR001B. The expiration date is April 3, 2026. The product was distributed nationwide in the U.S.
The recall addresses the presence of particulate matter in the product, specifically glass-like particles. These particles pose a risk of injury if injected, leading to potential complications.
There are no specific incident reports or injuries mentioned related to this recall. The potential for harm is classified as high due to the nature of the particulate hazard.
Consumers and healthcare providers should stop using the recalled product immediately. For further guidance, contact Imprimis NJOF, LLC or your healthcare provider directly.
For questions, consumers can contact Imprimis NJOF, LLC at their facility located at 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. More information is available at the FDA's recall notice: https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0250-2026.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.